Parallel paths to predictive biomarkers in oncology: Uncoupling of emergent biomarker development and phase III trial execution.
Where this comes from
- Record sourced from PubMed, PMID 20368158.
- Also identified by DOI 10.1126/scitranslmed.3000287.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
It is within pivotal phase III clinical trials that predictive biomarkers have the greatest potential to affect clinical practice by targeting drugs under development to relevant patient subgroups. Predictive biomarkers can be integrated into phase III clinical trials by a variety of approaches, including trial designs that uncouple the processes and actively anticipate the emergence of new biomarkers during trial execution. Here we describe the various approaches in an oncology context.
Medical subject headings
- Biomarkers, Tumor
- Clinical Trials, Phase III as Topic
- Medical Oncology